Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes

Vaccine

Volumn 21, Issue 23, 2003, Pages 3143-3148

  Arakawa, Takeshi ^a   Tsuboi, Takafumi ^b,h   Kishimoto, Ayano ^a   Sattabongkot, Jetsumon ^c   Suwanabun, Nantavadee ^c   Rungruang, Thanaporn ^b   Matsumoto, Yasunobu ^d   Tsuji, Naotoshi ^e   Hisaeda, Hajime ^f   Stowers, Anthony ^g   Shimabukuro, Isao ^a   Sato, Yoshiya ^a   Torii, Motomi ^b  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d UNIVERSITY OF TOKYO   (Japan)

^e NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^f UNIVERSITY OF TOKUSHIMA   (Japan)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h EHIME UNIVERSITY   (Japan)

Author keywords

Malaria; Mucosal; Vaccine

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MALARIA VACCINE; MEMBRANE PROTEIN; PROTEIN PVS25; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOPHELES; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GAMETOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MIDGUT; MOSQUITO; MOUSE; NONHUMAN; NORMAL HUMAN; NOSE MUCOSA; OOCYST; PARASITE TRANSMISSION; PLASMODIUM VIVAX; PRIORITY JOURNAL; TH2 CELL;

EID: 12444342650     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00258-5     Document Type: Article

References (24)

1. Mendis K., Sina B.J., Marchesini P., Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:2001;97-106.
2. Breman J.G. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64:2001;1-11.
3. Tsuboi T., Cao Y.M., Hitsumoto Y., Yanagi T., Kanbara H., Torii M. Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity. Infect. Immun. 65:1997;2260-2264.
4. Carter R. Transmission blocking malaria vaccines. Vaccine. 19:2001;2309-2314.
5. Tsuboi T., Tachibana M., Kaneko O., Torii M. Transmission-blocking vaccine of vivax malaria. Parasitol. Int. 52:2003;1-11.
6. Kocken C.H., Jansen J., Kaan A.M.et al. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum. Mol. Biochem. Parasitol. 61:1993;59-68.
7. Williamson K.C., Criscio M.D., Kaslow D.C. Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230. Mol. Biochem. Parasitol. 58:1993;355-358.
8. Carter R., Graves P.M., Keister D.B., Quakyi I.A. Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 12:1990;587-603.
9. Read D., Lensen A.H., Begarnie S., Haley S., Raza A., Carter R. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol. 16:1994;511-519.
10. van Dijk M.R., Janse C.J., Thompson J.et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell. 104:2001;153-164.
11. Kaslow D.C., Bathurst I.C., Lensen T., Ponnudurai T., Barr P.J., Keister D.B. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun. 62:1994;5576-5580.
12. Gozar M.M., Price V.L., Kaslow D.C. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 66:1998;59-64.
13. Lobo C.A., Dhar R., Kumar N. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect. Immun. 67:1999;1688-1693.
14. Stowers A.W., Keister D.B., Muratova O., Kaslow D.C. A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies. Infect. Immun. 68:2000;5530-5538.
15. Gozar M.M., Muratova O., Keister D.B., Kensil C.R., Price V.L., Kaslow D.C. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Exp. Parasitol. 97:2001;61-69.
16. Tsuboi T., Kaslow D.C., Gozar M.M., Tachibana M., Cao Y.M., Torii M. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 4:1998;772-782.
17. Hisaeda H., Stowers A.W., Tsuboi T.et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68:2000;6618-6623.
18. Ogra P.L., Faden H., Welliver R.C. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14:2001;430-445.
19. Saito M., Otake S., Ohmura M.et al. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant. J. Infect. Dis. 1:2001;823-826.
20. Yamamoto M., McGhee J.R., Hagiwara Y., Otake S., Kiyono H. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand. J. Immunol. 53:2001;211-217.
21. Goto N., Maeyama J., Yasuda Y.et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine. 18:2000;2164-2171.
22. Haq T.A., Mason H.S., Clements J.D., Arntzen C.J. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science. 268:1995;714-716.
23. Arakawa T., Chong D.K., Merritt J.L., Langridge W.H. Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res. 6:1997;403-413.
24. Arakawa T., Yu J., Chong D.K., Hough J., Engen P.C., Langridge W.H. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat. Biotechnol. 16:1998;934-938.